Siemens’ PETNET to manufacture [F-18]MK-6240 for Cerveau’s trial in US

12 February 2017 (Last Updated February 12th, 2017 18:30)

Siemens’ PETNET Solutions, a division of Siemens Medical Solutions USA, has signed an agreement with diagnostics firm Cerveau Technologies to manufacture an early stage investigational PET imaging agent [F-18]MK-6240.

Siemens’ PETNET Solutions, a division of Siemens Medical Solutions USA, has signed an agreement with diagnostics firm Cerveau Technologies to manufacture an early stage investigational PET imaging agent [F-18]MK-6240.

Under the terms of the agreement, the initial clinical trial material of [F-18]MK-6240 will be used at select US radiopharmacies.

The imaging agent is currently being studied for imaging of neurofibrillary tangles (NFTs) in the brain, which are commonly found in neurodegenerative diseases such as Alzheimer’s disease.

"Our collaboration with Cerveau reinforces our commitment to help fight the world's most challenging diseases, such as Alzheimer's."

Siemens’ PETNET Solutions chief executive officer Barry Scott said: “Siemens' PETNET Solutions looks forward to closely collaborating with Cerveau.

"Our in-depth manufacturing expertise and large network of radiopharmacies will be key in supporting the availability of this investigational PET imaging agent.

“Our collaboration with Cerveau reinforces our commitment to help fight the world's most challenging diseases, such as Alzheimer's.”

Cerveau intends to leverage the PET manufacturing and dispensing capabilities of Siemens’ PETNET for its MK-6240 clinical programme.

Cerveau Technologies president and chief executive officer Rick Hiatt said: “At Cerveau, we are focused on providing information and technologies to researchers and clinicians to enable the improvement of brain health.

"We are excited by the opportunity to work with PETNET Solutions in providing access to this novel imaging agent to the broader scientific community.”

Siemens' PETNET manufactures and dispenses PET radiopharmaceuticals for hospitals, clinics and research facilities and operates manufacturing facilities across 50 locations.

Formed as a partnership between Enigma Biomedical Group and Sinotau Pharmaceutical Group, Cerveau develops diagnostics and technologies to treat  neurodegenerative disorders.